CCMI
VKTX icon

Creative Capital Management Investments’s Viking Therapeutics VKTX Stock Holding History

Creative Capital Management Investments’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$5.3K – 333
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 248
2025
Q1 		$4.83K Hold
200
– – ﹤0.01% 204
2024
Q4 		$8.05K Hold
200
– – ﹤0.01% 199
2024
Q3 		$12.7K Buy
+200
New +$11.7K 0.01% 161

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Creative Capital Management Investments's VKTX Position: Q3 2025 in Review

Creative Capital Management Investments sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 200 shares — an estimated $5.3K sold.

Creative Capital Management Investments first reported a position in VKTX in Q3 2024 and held it in 4 quarters. The position peaked at $12.7K in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Creative Capital Management Investments reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Creative Capital Management Investments sold 200 Viking Therapeutics shares in Q3 2025, an estimated $5.3K.
  • Creative Capital Management Investments first reported a position in Viking Therapeutics in Q3 2024 and held it in 4 quarters.
  • Creative Capital Management Investments's Viking Therapeutics position peaked at $12.7K in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Creative Capital Management Investments's 13F filing for Q3 2025, filed 23 Oct 2025.